Uncategorized
Ozurdex approved in EU for treatment of DME
The European Commission has extended marketing authorization for Ozurdex for the treatment of diabetic macular edema in certain patients, according to an Allergan press release.Under the marketing authorization extension, the dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) is indicated for adult patients with visual impairment due to diabetic macular edema who are pseudophakic, or who were unable to undergo noncorticosteroid therapy, according to the press release.